Last Updated : June 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Strattera | Atomoxetine hydrochloride | Attention deficit hyperactivity disorder | Do not list | Complete | ||
| Strattera | Atomoxetine hydrochloride | Attention deficit hyperactivity disorder | N/A | Complete | ||
| Strensiq | Asfotase alfa | Hypophosphatasia, pediatric-onset | List with criteria/condition | Complete | ||
| Stribild | Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir Disoproxil Fumarate | HIV infection | List with criteria/condition | Complete | ||
| Sublinox | Zolpidem tartrate | Insomnia | Do not list | Complete | ||
| Sublocade | buprenorphine | Opioid use disorder, treatment | Reimburse with clinical criteria and/or conditions | Complete | ||
| Suboxone | Buprenorphine/naloxone | Opioid drug dependence (Substitution treatment) | List with clinical criteria and/or conditions | Complete | ||
| Sunvepra | Asunaprevir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Sutent | Sunitinib malate | Pancreatic Neuroendocrine Tumour | Reimburse with clinical criteria and/or conditions | Complete | ||
| Sutent | Sunitinib | Gastrointestinal stromal tumour (GIST) | List with clinical criteria and/or conditions | Complete | ||
| Sutent | Sunitinib malate | Cancer, Metastatic renal cell carcinoma | Do not list | Complete | ||
| Sylvant | Siltuximab | Multicentric Castleman's disease (MCD) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Symdeko | tezacaftor/ivacaftor | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Symtuza | Darunavir/cobicistat/emtricitabine/tenofovir alafenamide | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
| Synjardy | Empagliflozin and metformin | Diabetes mellitus (Type 2) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tafinlar | Dabrafenib | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tafinlar & Mekinist in combo | Dabrafenib & Trametinib in combo | Melanoma Adjuvant Therapy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tafinlar & Mekinist in combo | Dabrafenib & Trametinib in combo | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tafinlar & Mekinist in combo | Dabrafenib & Trametinib in combo | Non-Small Cell Lung Cancer | Do not reimburse | Complete | ||
| Tafinlar and Mekinist | Dabrafenib and Trametinib | NSCLC BRAF V600 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tafinlar and Mekinist | dabrafenib and trametinib | Pediatric glioma with a BRAF V600E | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Tafinlar-Mekinist | dabrafenib trametinib | Advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation | Pending | |||
| Tagrisso | Osimertinib | Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tagrisso | osimertinib | Non-small cell lung cancer | Active | |||
| Tagrisso | Osimertinib | Non-Small Cell Lung Cancer (NSCLC) (first line) | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : June 30, 2024